MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized gain on
marketable securities, net...
$513K
(152.71%↑ Y/Y)
Comprehensive loss
-$64,410K
(51.15%↑ Y/Y)
Total other
comprehensive income
$513K
(152.71%↑ Y/Y)
Interest income
$7,637K
(-3.97%↓ Y/Y)
Non-cash royalty income
$3,815K
(99.32%↑ Y/Y)
Net loss
-$64,923K
(50.84%↑ Y/Y)
Total other income
$11,452K
(16.06%↑ Y/Y)
License And Service
$5,954K
Laboratory Research
Revenue
$1,872K
Loss from operations
-$76,375K
(46.19%↑ Y/Y)
Total revenue
$7,826K
(-58.19%↓ Y/Y)
Total costs and
expenses
$84,201K
(-47.59%↓ Y/Y)
Research and development
$52,645K
(56.75%↑ Y/Y)
General and
administrative
$21,972K
(-1.04%↓ Y/Y)
Licensing
$5,193K
(-59.00%↓ Y/Y)
Revaluation of contingent
consideration
$2,300K
(-8.00%↓ Y/Y)
Cost of revenue
$2,091K
(-25.11%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)